Mark Jacobson | executive |
Herriot Tabuteau | executive |
Nick Pizzie | executive |
Ari Maizel | executive |
Leonid Timashev | analyst |
Charles Duncan | analyst |
Ashwani Verma | analyst |
Asim Rana | analyst |
Jason Gerberry | analyst |
David Amsellem | analyst |
Joseph Thome | analyst |
Marc Goodman | analyst |
Graig Suvannavejh | analyst |
David Hoang | analyst |
Myles Minter | analyst |
Hunter Murdock | executive |
Eddie Hickman | analyst |
Matthew Kaplan | analyst |
Vikram Purohit | analyst |
Hello, and welcome to the Axsome Therapeutics Fourth Quarter and Full Year 2023 Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.It's now my pleasure to turn the call over to Chief Operating Officer, Mark Jacobson. Please go ahead, sir.
Good morning, and thank you all for joining us on today's conference call. This morning, we issued our earnings press release providing a corporate update and details of the company's financial results for the fourth quarter and full year of 2023.